Lightspeed Venture Partners and SR One led a $60m Series A round in Ancora Biotech.

Lightspeed Venture Partners and SR One, venture capital firms, led a $60m Series A round in Ancora Biotech, a biotechnology company. “While Lightspeed often invests in early-stage preclinical programs, our past relationship with Roland and his team, their expertise in antibody innovation and deals, plus the appeal of having two programs already in the clinic made the investment opportunity one we could not pass up. The strength of the Ancora team, combined with the opportunity potential of the wide range of indications the company is pursuing, ultimately led to Lightspeed co-leading the series A, with Galym Imanbayev, MD, joining the board,” Lightspeed Venture Partners investor.